# dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

> **NCT06072326** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 36 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus With Diabetic Nephropathy

## Interventions

- **DRUG:** Dapagliflozin (Forxiga®)
- **DRUG:** SC0062 strength 10mg
- **DRUG:** SC0062 and dapagliflozin

## Key facts

- **NCT ID:** NCT06072326
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-10-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06072326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06072326, "dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06072326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*